Donor T-cells transferred after allogeneic stem cell transplantation (alloSCT) can result in long-term disease control in myeloma by the graft-versus-myeloma (GvM) effect. However, T-cell therapy may show differential effectiveness against bone marrow (BM) infiltration and focal myeloma lesions resulting in different control and progression patterns. Outcomes of 43 myeloma patients who underwent T-cell-depleted alloSCT with scheduled donor lymphocyte infusion (DLI) were analyzed with respect to diffuse BM infiltration and focal progression. For comparison, 12 patients for whom a donor search was started but no alloSCT was performed, were analyzed. After DLI, complete disappearance of myeloma cells in BM occurred in 86% of evaluable patients. The probabilities of BM progression-free survival (PFS) at 2 years after start of donor search, alloSCT and DLI, were 17% (95% confidence interval 0-38%), 51% (36-66%), and 62% (44-80%) respectively. In contrast, the probabilities of focal PFS at 2 years after start of donor search, alloSCT and DLI, were 17% (0-38%), 30% (17-44%) and 28% (11-44%), respectively. Donor-derived T-cell responses effectively reduce BM infiltration, but not focal progression in myeloma, illustrating potent immunological responses in BM with only limited effect of T-cells on focal lesions.
INTRODUCTION
Multiple myeloma (MM) is a neoplasia of plasma cells characterized by diffuse bone marrow (BM) plasmacytosis and focal lesions like plasmacytomas and lytic bone lesions. Current treatment strategies for fit younger patients aim to obtain long-term remissions and consist of combinations of immunomodulation, chemotherapy and autologous stem cell transplantation. 1 However, most patients eventually relapse, and these patients require other treatment strategies. The role of allogeneic stem cell transplantation (alloSCT) as treatment option for relapsed MM is currently under debate. [2] [3] [4] [5] [6] [7] [8] However, important lessons can be learned from the effect of T-cell therapy in the context of alloSCT. This may help to further develop T-cell therapy exploiting chimeric antigen receptor (CAR) cells, which is increasingly being performed. 9 AlloSCT can result in long-term control of the disease because immune-competent donor T-cells can exert efficient graft-versusmyeloma (GvM) effects. [10] [11] [12] Conventional outcome parameters of interest after transplantation are overall survival (OS) and progression-free survival (PFS). However, these outcomes offer little insight into the kinetics of the disease and the impact of different components of the treatment. The complexity of the course of the disease with occurrence of GvM effects, graft-versushost disease (GvHD) or non-relapse mortality, requires a richer methodology capable of analysing multiple distinct event types. A multi-state model permits mapping of all relevant events, 13 and from this several competing risks models can be derived to analyse the events of main interest. [14] [15] [16] [17] [18] At present, little is known about the clinical kinetics of allo-reactive T-cells in controlling myeloma progression or inducing tumor regression. Efficient GvM responses require targeting of malignant cells by antigen-specific T-cells in all sites of myeloma infiltration. Homing of T-cells to BM has been found to occur constitutively, whereas homing to other tissues may need specific ligands on T-cells, or an inflammatory environment. [19] [20] [21] Consequently, the strength of immune responses in BM and focal lesions may differ and result in differential progression patterns of myeloma after alloSCT and donor lymphocyte infusion (DLI) depending on the presence or absence of donor T-cell-mediated GvM reactivity. [22] [23] [24] Precise analyses of T-cell-mediated GvM responses is impaired in T-cell replete alloSCT settings by simultaneous effects of pretransplant treatment, conditioning regimens, concurrent immune responses, and immune suppression. T-cell depletion (TCD) of the stem cell graft has been developed to prevent development of severe GvHD. [25] [26] [27] In general, effective TCD obviates the need for prophylactic immunosuppression. 25, 27 However, TCD also adversely affects post-transplant anti-tumor immunity. 28 To overcome this effect, our center has pioneered routine administration of DLI at pre-scheduled time points while maintaining a low risk of GvHD induced by the conditioning regimen.
11,29-32 TCD-alloSCT with sequential DLI, i.e., systematic introduction of post-transplant immune therapy, has the benefit of offering a unique opportunity to assess the specific influence of donor lymphocytes on myeloma progression patterns since chemotherapy and the immune intervention are given at different points in time.
We hypothesized that alloSCT, and especially donor lymphocytes, modulate patterns of disease progression in MM. To test this hypothesis, BM and focal progression were assessed as separate events in a cohort of patients who underwent TCD-alloSCT with scheduled DLI and compared with outcomes of a cohort who did not undergo alloSCT, representing the course of the disease without TCD-alloSCT.
MATERIALS AND METHODS

Patient population
We analyzed data of all 43 MM patients who underwent in vivo and ex vivo T-cell depleted reduced-intensity conditioning (RIC) alloSCT at Leiden University Medical Center (LUMC) between May 2002 and July 2010 (alloSCT cohort). We also analyzed data of all 12 MM patients for whom a donor search was started at the LUMC during the same time period, but no alloSCT was performed (donor-search-no-alloSCT cohort; see Supplementary Material). The study was approved by Leiden University Medical Center Research Ethics Committee. Informed consent was obtained prior to data collection. Data was analyzed as of March 2015.
Definitions
Focal progression was defined as an increase in size or new-onset of soft tissue plasmacytomas and/or bone lesions as described by the criteria of the international myeloma working group. 33 New-onset BM infiltration (i.e., BM progression) was defined as ⩾ 10% diffuse myeloma infiltration after a previously negative BM sample (measured by morphology, immunophenotyping and/or trephine biopsy). In all other cases, BM progression was defined as ⩾ 5% increase of myeloma cells in the BM as compared with the previous BM sample. After alloSCT, BM progression was considered as primary failure. Therefore, a lower threshold was chosen to detect newonset BM involvement as early as possible: any percentage of myeloma cells in the BM with loss of donor chimerism (⩽90% donor chimerism). Progression mortality was defined as death after signs of progressive disease. Non-progression mortality after alloSCT (or DLI) was defined as death after alloSCT (or DLI) without signs of progressive disease between alloSCT (or DLI) and death, respectively.
AlloSCT protocol
Patients with relapsed MM were eligible for alloSCT if the disease was responsive to drug therapy and a HLA-matched (9/10 or 10/10) related or unrelated donor was available. Details about the RIC alloSCT protocol and T-cell depletion are provided in the Supplementary File. Due to ex vivo TCD patients did not require additional GvHD prophylaxis. For follow-up after alloSCT, see Supplementary Material.
Administration of DLI
After engraftment, all patients without GvHD requiring systemic immunosuppression were eligible for DLI from 6 months after alloSCT in case of mixed-chimerism or disease progression. DLI-dosing depended on the time interval from alloSCT and on donor type (see Supplementary Material for details).
Statistical analysis
Time was measured from the start of donor search (donor-search-noalloSCT cohort), infusion of donor stem cells, or DLI (alloSCT cohort). Probabilities of overall survival with associated 95% confidence intervals (95% CI) were calculated by the Kaplan-Meier method and compared by the log-rank test. Survival curves for different groups were compared using a log-rank test. Statistical software used was SPSS, PASW Statistics 20, release 20.0.0 (2011) and R 3.1.0 (http://www.r-project.org/foundation), packages 'prodlim', 'survival', 'cmprsk' and 'mstate'. 18 Code is available from the corresponding author upon reasonable request.
Multi-state model and competing risks analysis
Multi-state models were developed as schematic representations of all events relevant to the different analyses of outcomes after alloSCT and start of donor search, respectively ( Figure 1) . A detailed explanation of the model is provided in the Supplementary Material. These models were the basis for the estimation of the outcomes of interest by means of different competing risks analyses. Two separate competing risks models were constructed for estimating cumulative incidences of focal and BM progression from alloSCT taking place either before or after DLI with death without focal and BM progression, respectively, as a competing event. Statistical tests were developed to compare the cumulative incidences of focal and BM progression within one group at different points in time (see Supplementary Material for details).
RESULTS
Donor-search-no-alloSCT cohort
Baseline characteristics of the donor-search-no-alloSCT cohort are presented in Table 1 . Reasons for not performing an alloSCT were: no suitable donor found (n = 6), patient decision (n = 3), poor WHO status (n = 2) and rapidly progressive disease (n = 1). The cumulative incidences of BM and focal progression at 2 years after start of donor search were 67% (95% CI 40-93%), and 50% (95% CI 22-78%), respectively (Table 2; Figure 2a ). The probability of BM PFS, and focal PFS at 2 years after start of donor search were The starting state of all patients in this model was the day of infusion of the donor stem cell graft (alloSCT). All events after alloSCT were recorded at first occurrence only, therefore each patient could only make each transition once and could not return to a state previously visited. The events after alloSCT were development of focal progression (focal progression I), diffuse bone marrow infiltration (BM progression I), as well as the first donor lymphocyte infusion (DLI). Focal and BM progression after DLI were indicated by the states Focal progression II and BM progression II, respectively. The arrows between the two progression states indicate that patients could show BM after focal progression and vice versa. Events which are considered to be associated with a favorable outcome are depicted by a green box, myeloma-related events by a yellow box.
Transitions to favorable and unfavorable events are depicted by green and red arrows, respectively. The endpoints non-progression mortality and progression mortality are depicted by a gray box.
(b) A model for the analysis of progression patterns after start of donor search in the donor-search-no-alloSCT cohort. The starting state of all patients in this model was the day of start of donor search. The events after start of search were development of focal progression (focal progression), and BM progression (BM progression). The clinical endpoint Mortality is depicted by a gray box. No distinction was made between death with and without progression. A full colour version of this figure is available at the Bone Marrow Transplantation journal online.
Donor T-cell responses M Eefting et al both 17% (95% CI 0-38%). Estimated 2-year overall survival since donor search was 42% (95% CI 14-70%). In conclusion, BM progression was observed frequently in patients for whom alloSCT was scheduled, but not performed.
Outcomes after alloSCT Baseline characteristics of the alloSCT cohort are presented in Table 1 . Patients of the two cohorts had similar risk characteristics, and prior treatment lines, but patients of the donor-search-no-allo were slightly older at the time of search. After alloSCT, one patient did not engraft and rejection was observed in one patient. Overall, six of 41 patients (15%) with persisting engraftment required systemic immunosuppression for treatment of GvHD after engraftment. Median follow-up of patients alive at last follow-up was 96 months (range 65-117 months). Estimated overall survival since alloSCT of the entire cohort was 60% (95% CI 46-75%, Figure 3 ) at 2 years and 32% (95% CI 16-47%) at 7 years (see Supplementary Material for details).
Overall survival of patients transplanted with sibling donors or unrelated donor were similar (P = 0.67). In addition, overall survival of patients who underwent up-front tandem auto-/alloSCT did not differ significantly from patients who underwent alloSCT after relapse (P = 0.38).
DLI
In total, 29 patients received DLI (n = 15 sibling donor, n = 14 unrelated donor). See Supplementary Files for details of not receiving DLI. Median time to first DLI was 258 days (range 132-560 days). At 12 and 24 months after alloSCT the probability of having received DLI was 56% (95% CI 41-71%), and 67% (95% CI 53-82%), respectively (see Figure 4) . Overall, 11 of 29 patients (38%) required systemic immunosuppression for tapering of GvHD after DLI, of whom two patients died due to GvHD-related complications (see Supplementary Material for details).
BM and focal progression after alloSCT Cumulative incidences of BM progression at 24 and 60 months post-transplant were 30% (95% CI 17-44%) and 35% (95% CI 21-49), respectively (Table 2; Figure 2b ). Cumulative incidences of focal progression at 24 and 60 months post transplant were 47% (95% CI 32-61%) and 56% (95% CI 41-71%), respectively. When testing whether both types of progression occurred with the same frequency, it was found that the significance of the difference tended to increase over time (e.g., a borderline significant difference at 2 years after alloSCT (P = 0.08)).
The probabilities of BM PFS at 24 and 60 months post transplant were 51% (95% CI 36-66%), and 33% (95% CI 19-47%) respectively. The probabilities of focal PFS at 24 and 60 months post transplant were 30% (95% CI 17-44%), and 21% (95% CI 9-33%) respectively.
Disappearance of BM disease after DLI In seven patients, at least one DLI was administered for BM progression. After DLI, six of these seven patients (86%) converted to full-donor hematopoiesis with disappearance of myeloma cells in BM. One patient failed to show a response and died.
Cumulative incidences of BM progression at 24 and 60 months post-DLI were 17% (95% CI 3-31%) and 21% (95% CI 6-35%), respectively (Table 2; Figure 2c ). Cumulative incidences of focal progression at 24 and 60 months post-DLI were 62% (95% CI 44-80%) and 69% (95% CI 52-86%), respectively. A test comparing 
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the incidence of focal progression to that of BM progression, both after DLI, yielded significant differences from 4 months after DLI onward (e.g., P o0.001 at 24 months). The probabilities of BM PFS at 24 and 60 months post-DLI were 62% (95% CI 44-80%), and 48% (95% CI 30-66%) respectively. The probabilities of focal PFS at 24 and 60 months post DLI were 28% (95% CI 11-44%), and 21% (95% CI 6-35%), respectively.
Finally, similar focal progression patterns were observed in patients without GvHD after DLI as compared with patients with severe GvHD after DLI (see Supplementary File for details).
DISCUSSION
Here we present the first systematic analysis of differential progression patterns in patients with MM following RIC alloSCT and DLI. Due to close follow-up, detailed long-term follow-up data were available after alloSCT and DLI, which facilitated assessment of BM and focal progression as separate outcomes.
Firstly, TCD effectively reduced occurrence of severe GvHD early after alloSCT. Therefore, DLI could be administered in most patients. DLI resulted in long-term use of systemic immunosuppression in only 7% of patients, and only two patients died from non-progression mortality after DLI (median follow-up 7 years). Secondly, DLI induced BM remission in almost all patients with BM progression prior to DLI. Furthermore, BM progression occurred in fewer than 20% of patients at 2 years after DLI. In contrast, during follow-up focal progression was observed in the majority of patients (62% at 2 years after DLI). Therefore, DLI appears to be highly effective in controlling myeloma infiltration in BM, but lack of focal disease control restricts cure to a minority of patients. The estimated OS at 2-year was 60% and 32% at 7 years, corresponding to previous reports. 4, 25 This study was not designed as a randomized trial. As controls, we therefore selected a cohort of patients with a similar intentionto-treat as our alloSCT cohort, i.e., patients who were referred to our hospital for a donor search, but did not undergo alloSCT. The low number of patients in this group reflects that that it was possible to give the intended treatment to the large majority of eligible patients. The main reason for not performing an alloSCT was lack of a suitable donor. Myeloma progression patterns were as expected with active BM disease in most patients. 34 The probability of BM PFS at 2 years after start of donor search was low (17%) as compared with 2 years after alloSCT (51%) and especially after DLI (62%). In contrast to the alloSCT cohort, in the control cohort BM examinations were performed at the discretion of the treating physician, and we chose a higher threshold to detect clinically relevant disease only, which may have even contributed to potential underreporting of BM progression. Thus, BM progression occurs frequently in patients for whom alloSCT was scheduled, but not performed.
Incidence of focal progression was more similar for both groups (50% versus 47% at 2 years for the donor-search and alloSCT cohort, respectively). However, the probability of focal PFS was higher in the alloSCT cohort (30% versus 17% at 2 years), implying that among patients alive, relatively fewer had a focal progression in this cohort, suggesting restricted efficacy of alloSCT against focal progression. The large and significant difference between focal and BM progression after DLI supports the interpretation that absence of BM progression results in a longer survival, thereby giving the opportunity to develop focal progression.
Myeloma cells are responsive to immunotherapy, which is supported by the frequent responses after DLI in patients with residual BM disease in our cohort. 30 Correspondingly, conversion to full-donor chimerism following DLI is associated with disease response in patients with MM. 12 Several groups tried to enhance this effect by combining DLI with immune modulatory drugs, such as thalidomide, bortezomib, and lenalidomide. [35] [36] [37] This resulted in partial and complete remissions, but cure was only achieved in a minority of patients. Also, repeated DLI does not result in new long-term remissions, especially not in the extramedullary compartment. 24, 38 In patients responding to DLI, polyclonal immune responses targeting allo-antigens have been demonstrated. 39 In particular, if hematopoiesis associated polymorphic antigens including minor histocompatibility antigens are targeted, GvM responses will occur. 39 In general, memory T-cells show preferential homing towards the BM, and therefore in the BM environment strong immune responses are induced. 40 Our study demonstrates that despite effective immune responses after DLI, leading to disease control in the BM, the majority of patients ultimately showed progressive focal disease. Correspondingly, due to a significant incidence of extramedullary disease, repeated chimerism measurements have limited impact on the management of MM after T-cell repleted alloSCT. 41 In general, the strength of an allo-immune response appears to correlate with occurrence of GvHD. 42 However, a strong immune Abbreviations: alloSCT = allogeneic stem cell transplantation; BM = bone marrow; DLI = donor lymphocyte infusion. BM progression was analyzed in a competing risks model in which death before BM progression was considered as a competing event. Therefore, at each time point the sum of the probability to be alive without BM progression (BM PFS) and the cumulative incidences of BM progression and death before BM progression must add up to 100%. At the start time point, the two cumulative incidences are 0. Analogous statements hold for focal progression. Outcomes are given at 12, 24 and 60 months after the respective start points. Outcomes at 60 months after start of donor search are not shown because of the small number of patients at risk beyond 24 months.
Donor T-cell responsesresponse does not prevent disease progression and is not associated with prolonged disease remission. 43 These observations are especially important in a context where MM is used as a model for the process of metastasis, 44 because they pinpoint the biological difference of immunological behavior of donor T-cells inside and outside the BM.
The question remains why the sensitivity of myeloma cells for immunotherapy seems to be restricted to BM. 24 Several factors may have a role. For instance, the tumor cells in focal lesions may selectively downregulate expression of tumor antigens. This type of immune evasion may be overcome by induction of a local danger signal, for instance by a combination of radiotherapy and administration of interferon, which stimulates T-cell responses. 45, 46 Secondly, tumor-infiltrating donor T-cells may be capable of recognizing myeloma cells in focal lesions, but their function can be inhibited by myeloma cells and their microenvironment. 47 For the communication of myeloma cells and with their microenvironment, immune checkpoint pathways have an important role. 48 Therapeutic blockade of these pathways has become a paradigmshifting treatment in solid tumors and more recently in hematologic malignancies, including myeloma. 49 For instance, ipilimumab can restore anti-tumor reactivity through a graftversus-tumor effect, including relapsed extramedullary leukemia. 50 Combining DLI with immune checkpoint pathway inhibitors is an interesting strategy for future studies targeting both BM and focal progression of myeloma.
In conclusion, our study shows that T-cell therapy in the context of alloSCT modifies the natural course of myeloma and specifically appears to be highly effective in controlling BM infiltration. However, only a minority of patients will be cured by the potent GvM effect from DLI due to the limited effect on focal lesions. However, the benefit of long-term absence of diffuse BM infiltration after DLI may form the basis for clinical trials where T-cell therapy is augmented by treatment modalities which preferentially target focal myeloma progression.
